HeartFlow 9.0.0

The HeartFlow mobile app provides a convenient tool for clinicians to access their patients' HeartFlow FFRct Analyses. Users can easily review a roster of patients within their institution who have undergone the HeartFlow Analysis, and observe their personalized 3D models along with FFRct values.

For those who are not currently utilizing HeartFlow services but wish to explore the HeartFlow Analysis, a quick introduction experience is available to preview the 3D model.

It's worth noting that there are significant distinctions in how FFRct values are displayed on the mobile app. For further clarification, inquiries can be directed to HeartFlow Support at [email protected].

About HeartFlow:

HeartFlow is revolutionizing the approach to diagnosing and managing cardiovascular disease through its innovative technologies.

The HeartFlow FFRct Analysis is a non-invasive cardiac assessment that generates a customized 3D heart model. This tool empowers clinicians to assess cardiac blood flow and determine the best course of treatment for patients suspected of having coronary artery disease (CAD).

• It is a regulated medical device with FDA 510(k) clearance, CE mark, and PMDA approval.
• Backed by extensive clinical research, supported by over 500 peer-reviewed articles.
• Approved for reimbursement by Centers for Medicare and Medicaid Services (CMS) in the US.
• Endorsed by NICE and mandated by NHS England and NHS Improvement under the MedTech Funding Mandate.
• Accessed by over 235 million patients in the US through current health insurance coverage.
• Facilitates improved clinical outcomes by identifying CAD earlier, leading to an 83% reduction in unnecessary angiograms.*
• Aids in reducing healthcare costs, with a 26% reduction in mean one-year per-patient expenditures.*
• Utilizes deep learning for continuous enhancements in product precision and turnaround time.
• Enhances patient outcomes and quality of life* - testimonials from more than 100,000 patients are available on our website.

The HeartFlow FFRct Analysis is available for commercial use in the United States, Canada, Europe, and Japan. However, the HeartFlow Mobile Application is accessible for commercial purposes exclusively in the United States, Canada, and the UK.

If your institution does not currently have access to HeartFlow services, you can initiate a conversation by submitting a request via our website: Contact Us.

* Douglas et al., J Am Coll Cardiol 2016; 68:435-45